BIIB/ELN/TEVA/NVS/MNTA—Robyn Karnauskas of Deutsche Bank forecasts that US Tysabri sales will fall from $633M in 2010 to $376M in 2015 as newer and safer MS drugs reach the market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.